Fosun Pharma Release 2019 Interim Results：Continue to Increase R&D Investment with a Steady Growth in Pharmaceutical Manufacturing & R&D Segment

08-27 2019

【26 August 2019，Shanghai】On 26 August 2019, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (Fosun Pharma, stock code: 600196.SH，02196.HK), a leading healthcare group in China, anno...

Sisram Medical Ltd Announces Its Interim Results for the First Half of 2019, Showcasing 9.3% Revenue Growth Driven by Consumer-Centric Approach

08-21 2019

Hong Kong, August 20, 2019 -- Sisram Medical Ltd (“Sisram” or “the Company”; stock code: 1696.HK), an investment holding company specializing in medical technology for healthcare, ...

Fosun Pharma Transfers Partial Stake in United Family Healthcare Remaining as its Strategic Shareholder

07-30 2019

Hong Kong, July 30, 2019 - Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK), a Chinese leading healthca...

Marking a New Milestone in Overseas Markets Henliu’s HLX02, the First China-developed Trastuzumab Biosimilar Receives Marketing Authorization Application for Review from EMA

06-21 2019

Henlius trastuzumab biosimilar HLX02 has been accepted by the European Medicines Agency (EMA) for reviewing its Marketing Authorization Application (MAA) . HLX02 has established th...

Fosun Pharma’s Innovative Drug ORIN1001 Receives U.S. FDA Fast Track Designation, Marking a Milestone for the treatment of Triple-negative Breast Cancer

06-16 2019

SHANGHAI, June 16, 2019-Shanghai Fosun Pharmaceutical (Group) Co., Ltd.(“Fosun Pharma; stock code: 600196.SH, 02196.HK)), a leading healthcare group in China announced that its inv...